Proteotype Unveils Alchemi®, Data and Orchestration Platform for Enlighten®
Proteotype Unveils Alchemi®, the Data and Orchestration Platform Behind Enlighten®
Summary
Proteotype Diagnostics, based in Portugal, unveiled Alchemi, a proprietary data and clinical workflow platform. This platform is designed to support the company's investigational blood-based multi-cancer test, Enlighten, aiming to securely connect lab measurements and multi-country clinical data while enhancing interoperability across healthcare settings.
Details
Proteotype Diagnostics announced Alchemi at its Torres Vedras site in Portugal. This proprietary platform is designed for the company's investigational blood-based multi-cancer test, Enlighten. The development program begins on September 1, 2026, supported by approximately €499,000 from the European Innovation Council’s Pre-Accelerator funding initiative. Alchemi connects laboratory measurements and multi-country clinical data through a secure digital infrastructure. It supports interoperability standards including HL7 FHIR and SNOMED CT to simplify local care pathways. CEO Wesley Sukdao stated that Alchemi provides the software infrastructure needed to transform lab measurements into reliable results, while the company is actively recruiting roles in software engineering, data engineering, and cybersecurity for this development.
Original content copyright by respective publishers